Faculty Summaries
Anthony J Olszanski
Anthony J. Olszanski, RPh, MD
Associate Professor
  • Director, Phase 1 Program

Selected Publications

  • Rini BI, Schiller JH, Fruehauf J et al. and Olszanski AJ, Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy. Lancet Oncology. In press.
  • Michael M, Vlahovic G, Khamly K, Pierce KJ, Guo F, Olszanski AJ. Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel with or without axitinib, a VEGFR inhibitor. Br J Cancer. 2010 Nov 9;103(10):1554-61. PubMed
  • Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. Efficacy and Safety of Axitinib in Patients with Advanced Non-Small Cell Lung Cancer: Results from a Phase II Study. J Clin Oncol. 2009 Aug 10;27(23):3836-41. PubMed
  • Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific PDGFR tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. PubMed
  • Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD. Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. Clin Cancer Res. 2007 Jun 1;13(11):3293-301. PubMed
  • Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A. Modulation of Cell-cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01. Clin Cancer Res. 2006 Dec 1;12(23):7079-85. PubMed